secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125337
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q3 2024 net loss $31.2M; cash $463.3M; positive Phase 1b naporafenib data
--------------------------------------------------------------------------------

- Net loss of $31.2M ($0.11/share) vs $30.4M ($0.20/share) in Q3 2023.
- Cash, equivalents, and marketable securities $463.3M; expected to fund operations into H1 2027.
- R&D expenses $27.6M (up from $25.2M YoY) driven by clinical and preclinical activities.
- Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib + trametinib in NRASm melanoma bolsters Phase 3 SEACRAFT-2 conviction.
- IND filings on track: ERAS-4001 pan-KRAS inhibitor Q1 2025, ERAS-0015 pan-RAS glue H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024125337/0000950170-24-125337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024125337/eras-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer